About biomerica - BMRA
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.
BMRA At a Glance
Biomerica, Inc.
17571 Von Karman Avenue
Irvine, California 92614
| Phone | 1-949-645-2111 | Revenue | 5.31M | |
| Industry | Medical Specialties | Net Income | -4,973,000.00 | |
| Sector | Health Technology | Employees | 54 | |
| Fiscal Year-end | 05 / 2026 | |||
| View SEC Filings |
BMRA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.319 |
| Price to Book Ratio | 1.892 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.069 |
| Enterprise Value to Sales | 0.954 |
| Total Debt to Enterprise Value | 0.09 |
BMRA Efficiency
| Revenue/Employee | 98,351.852 |
| Income Per Employee | -92,092.593 |
| Receivables Turnover | 7.265 |
| Total Asset Turnover | 0.699 |
BMRA Liquidity
| Current Ratio | 2.802 |
| Quick Ratio | 1.945 |
| Cash Ratio | 1.379 |
BMRA Profitability
| Gross Margin | 9.377 |
| Operating Margin | -96.724 |
| Pretax Margin | -93.617 |
| Net Margin | -93.636 |
| Return on Assets | -65.439 |
| Return on Equity | -92.988 |
| Return on Total Capital | -108.985 |
| Return on Invested Capital | -88.37 |
BMRA Capital Structure
| Total Debt to Total Equity | 11.157 |
| Total Debt to Total Capital | 10.037 |
| Total Debt to Total Assets | 7.704 |
| Long-Term Debt to Equity | 2.436 |
| Long-Term Debt to Total Capital | 2.192 |